Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
KPV (lysine-proline-valine, the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH)) is a small synthetic peptide that has gained attention as an anti-inflammatory agent with potential applications in inflammatory bowel disease, skin inflammation, and other inflammatory conditions.
The compound represents an interesting case in peptide pharmacology: the smallest active fragment of a larger natural hormone that retains anti-inflammatory activity while losing other receptor-binding properties (pigmentation, appetite, sexual function) of the parent molecule.
The compound corresponds to amino acids 11–13 of the full 13-amino acid α-MSH. The unique feature of KPV is that it retains substantial anti-inflammatory activity of α-MSH while lacking the receptor binding sequence responsible for pigmentation, appetite, and arousal effects of the parent hormone. This makes KPV theoretically attractive as a "clean" anti-inflammatory peptide with reduced side effect potential.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Oral capsules | Variable; rapid degradation balanced by ongoing PepT1 uptake |
| Subcutaneous injection (estimated) | ~1–2 hours |
| Topical formulations | Local action |
What it does
Main effects
- Anti-inflammatory activity in inflammatory bowel disease models: Kannengiesser et al. (2008) demonstrated earlier recovery, weight regain, and reduced colonic MPO activity in DSS and transfer colitis; rescued MC1R-deficient mice from death during DSS colitis (MCR-independent mechanism)
- PepT1-mediated direct intestinal effects: Dalmasso et al. (2008) established peptide transporter 1 uptake in intestinal epithelium; provides mechanistic basis for oral KPV efficacy in IBD without requiring systemic absorption
- NF-κB pathway modulation: reduction of NF-κB activation in inflammatory contexts; reduced pro-inflammatory gene expression (TNF-α, IL-1β, IL-6, IL-8)
- Effects on neutrophil and macrophage function: reduced neutrophil migration and MPO activity; macrophage polarization toward less inflammatory phenotypes
- Improved intestinal barrier function and reduced intestinal permeability in IBD models
- Skin inflammation effects: preclinical evidence in contact dermatitis, psoriasis-related, and atopic dermatitis models
- Lung inflammation effects: alveolar epithelial NF-κB modulation in endotoxin models
- "Clean" anti-inflammatory profile: lacks the melanocortin receptor binding responsible for pigmentation, appetite, and sexual-function effects of the parent α-MSH (positions 11–13 only)
- Oral bioavailability is meaningful via PepT1, unusual among injectable peptides
What to watch for
Common side effects
- No completed Phase 2 or Phase 3 human trials for any indication: no published human PK data, no human controlled safety data
- Generally favorable anecdotal tolerability: among the more favorable safety profiles in the research-peptide category; consistent with anti-inflammatory mechanism and natural-origin α-MSH fragment
- Mild local reactions at injection or application sites
- Theoretical immunosuppression concerns: could theoretically affect immune responses to infection, impair vaccine responses, or affect surveillance against malignancy; the anti-inflammatory mechanism is narrow compared to broad immunosuppressants
- Theoretical concerns about suppressing beneficial chronic inflammation: some chronic inflammation may serve protective functions
- Effects in conditions where inflammation is beneficial (acute infections, certain healing contexts): uncharacterized
- No long-term human safety data: multi-year continuous use entirely uncharacterized
- Quality concerns for research chemical supply: standard identity, purity, concentration, sterility concerns
- Should not substitute for evidence-based IBD therapy: TNF inhibitors and other approved biologics have substantial Phase 3 evidence that KPV does not
- Cannot definitively replicate parent-α-MSH receptor-mediated effects that some users may expect
Key facts
Key facts worth knowing
- KPV is a simple tripeptide (Lys-Pro-Val, 384 Da), among the smallest peptides with documented biological activity. The sequence corresponds to the C-terminus of alpha-MSH (positions 11–13 of the 13-amino acid parent hormone).
- The compound has substantial preclinical evidence for anti-inflammatory effects, particularly in inflammatory bowel disease (IBD). Multiple animal studies in DSS-induced colitis and TNBS-induced colitis have demonstrated significant anti-inflammatory effects [Kannengiesser et al. 2008, Inflammatory Bowel Diseases]. Kannengiesser K et al., Inflammatory Bowel Diseases 2008;14(3):324-331
- Mechanism is unusual: Anti-inflammatory effects appear to be at least partially independent of melanocortin receptor (MCR) signaling. KPV may act through PepT1 (peptide transporter 1), a peptide transporter expressed in intestinal epithelium, providing a mechanism for direct intestinal effects without systemic exposure. Dalmasso G et al., Gastroenterology 2008;134(1):166-178
- KPV is NOT pigmentation-affecting: Unlike the full α-MSH peptide, KPV does not bind the melanocortin receptors involved in skin and hair pigmentation. This is sometimes cited as an advantage over melanotan-1 and melanotan-2 (which produce pigmentation as both desired and side effect).
- Human clinical evidence is limited. The primary evidence base remains preclinical (animal and cell studies). While IBD applications have been pursued for some time, FDA-approved KPV-based therapy has not emerged.
- The compound is used both orally and by injection outside medical settings, with the standard caveats of unregulated peptide supply (identity, purity, concentration, sterility).
- Side effect profile appears favorable in available data: the anti-inflammatory mechanism without pigmentation/appetite/sexual effects makes the theoretical side effect profile cleaner than for full α-MSH analogs. WADA status: Not currently prohibited.
Legal status
Legal status
No FDA approval. Sale for human consumption is in legal grey area. Research chemical sale exists with "not for human consumption" disclaimer. Compounding through 503A pharmacies has been progressively restricted. Not a controlled substance. Not WADA-prohibited.